Rezolute appoints Sunil Karnawat as chief commercial officer

REDWOOD CITY, Calif. - Rezolute, Inc. (NASDAQ:RZLT), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), has appointed Sunil Karnawat as Chief Commercial Officer, effective August 18, 2025. The company, with a market capitalization of $562 million and strong liquidity position reflected in its 8.43 current ratio, has shown impressive momentum with a 40% price return over the past six months.

Karnawat brings over 25 years of experience in global commercialization of biopharmaceuticals and medical devices. Prior to joining Rezolute, he served as a Vice President at Cytokinetics and Ultragenyx, where he led commercial functions in launching four ultra-rare disease products. InvestingPro analysis shows the company maintains a healthy balance sheet with more cash than debt, though it’s not yet profitable, with analysts expecting continued losses this year.

At Rezolute, Karnawat will be responsible for developing the launch strategy and global market readiness for ersodetug, the company’s antibody therapy currently in Phase 3 studies for both congenital and tumor hyperinsulinism.

"His proven track record of successfully bringing therapies to patients across multiple therapeutic areas speaks to both his commercial expertise and deep commitment to serving patients with high unmet need," said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute, in a press release statement.

Karnawat’s previous experience includes leadership roles at Myriad Genetics, Vivus Pharmaceuticals, and Novo Nordisk, where he supported the U.S. launch of Victoza. He holds an MBA from the Wharton School of Business, a Ph.D. and M.S. in Engineering from North Dakota State University, and a B.E. in Civil Engineering from the College of Engineering in Pune, India.

In connection with his appointment, Rezolute’s Board of Directors approved an inducement stock option grant of 275,000 shares of common stock with an exercise price of $6.55 per share, equal to the closing price on August 18, 2025. The stock is currently trading near its 52-week high of $6.64, with analyst price targets ranging from $9 to $15. According to InvestingPro’s Fair Value model, the stock appears slightly overvalued at current levels. Discover more insights and 8 additional ProTips for RZLT, along with comprehensive analysis for 1,400+ US stocks, with an InvestingPro subscription.

In other recent news, Rezolute has made significant advancements in its clinical and financial activities. The company has updated its financial model to reflect actual earnings from the second and third quarters of fiscal year 2025, alongside a recent capital raise. Cantor Fitzgerald has reiterated its Overweight rating on Rezolute, although a specific price target was not disclosed. Additionally, BTIG maintained a Buy rating with a $15 price target, emphasizing the completion of enrollment in the sunRIZE clinical trial, which surpassed initial expectations with 62 participants.

The sunRIZE study, a Phase 3 clinical trial, has posted a patient demographic poster, providing detailed information about the participants. This material has been made publicly available on Rezolute’s website and filed with the Securities and Exchange Commission. Furthermore, Rezolute’s drug ersodetug has received Breakthrough Therapy Designation from the FDA for congenital hyperinsulinism and tumor-induced hypoglycemia. The company plans to file a Biologics License Application for ersodetug in mid-2026, following the anticipated release of top-line data from the sunRIZE study in December 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.